Obesity Pharmacotherapy

Obesity Pharmacotherapy

Obesity pharmacotherapy encompasses the use of approved medications to achieve clinically meaningful weight loss in individuals for whom lifestyle modifications alone have proven insufficient. Current treatment guidelines generally recommend pharmacotherapy for adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The pharmacological approach to obesity has evolved significantly over the past decade, shifting from older centrally-acting appetite suppressants with limited efficacy and safety concerns to newer incretin-based therapies that have redefined expectations for achievable weight loss.

The current landscape of obesity pharmacotherapy includes several mechanistic classes. GLP-1 receptor agonists such as semaglutide have demonstrated weight reductions of approximately 15% to 17% of body weight in pivotal trials, establishing a new standard of care. Dual and triple receptor agonists are extending this efficacy further, with emerging agents producing weight loss approaching or exceeding that achieved by bariatric surgery. Beyond weight reduction, modern obesity pharmacotherapy is evaluated on its ability to improve cardiometabolic risk factors, reduce obesity-related comorbidities, and sustain benefits over long treatment durations.

Clinical Relevance to Retatrutide

Retatrutide represents a potential advancement in obesity pharmacotherapy, with phase 2 trial data demonstrating mean weight reductions of up to 24.2% at the highest dose over 48 weeks. If confirmed in phase 3 trials, this level of efficacy would position retatrutide among the most effective non-surgical obesity treatments available. The triple-agonist mechanism provides a pharmacological rationale for the enhanced weight loss observed, as the combination of appetite suppression, improved insulin sensitivity, and increased energy expenditure addresses multiple pathophysiological drivers of obesity simultaneously. Ongoing clinical development will determine whether retatrutide can secure regulatory approval as a chronic weight management therapy.